🚨Trade Alert 🚨 ATAI

With a price target of $21, ATAI may be trading at an obscene value as the psychedelics revolution gains momentum. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ Greetings All, Wall Street and renowned investors such as Peter Thiel are investing in the promise of psychedelics. Magic mushrooms, shrooms, ketamine, psilocybin, whatever you want to call them, this is the new frontier of mental health that is anticipated to be phenomenal in changing the landscape of how to treat many disorders. According to a WSJ article, “Wall Street is betting tens of millions of dollars on psychedelic drugs that backers say could treat mental illness for a fraction of what it costs to do therapy with [better-known treatments.”]( “The potential of psychedelics far exceeds the potential of cannabis,” thinks Shark Tank’s [Kevin O’Leary](. “What interested me is the scale and size of the market,” O’Leary said. “These opportunities have been ignored ever since the 1960s.” “This is a brand-new area of medicine with such incredible potential,” O’Leary added, and remarked that the way investors should be looking at it is based on the fact that we have not had new medicines for mental health approved in decades! Psychedelics could become the next multi-billion-dollar industry and it’s time to take notice. This puts attention on a growing NASDAQ company called Atai Life Sciences, which trades under the ticker symbol “ATAI.” ATAI is a German-based company that IPOed in mid-2021 and could have the right solutions to solve a very challenging problem. With multiple clinical-stage programs aimed at addressing significant unmet patient needs in mental health and the capital to fund the company into the first half of 2026, ATAI looks like one of the strongest contenders to becoming a frontline leader in the psychedelics boom! The company has plenty of cash on hand to the tune of $227 MILLION as reported in the company’s last financial report. Plenty of BULLISH factors make ATAI a stock to watch closely as the discussion on psychedelics gets louder! [( NASDAQ: ATAI An exciting reason to have ATAI on your radar is the [high $21 price target]( on the stock. This price target implies a potential upside of nearly 1,500%!! The potential upside is nearly 300% at the low price target of $5.10. NASDAQ.com also currently has a "STRONG BUY" rating on the stock. ATAI is being covered by many notable analysts, including EF Hutton, H C Wainwright, and Cantor Fitzgerald. [NASDAQ's average price target among analysts is 14!]( That price target implies upside of nearly 1,000%! Another reason to be watching the company is that insider optimism is high. CEO Mr. Florian Brand recently made a significant purchase of [40,000 shares]( of the company's stock. His insider status provides him with a unique perspective on the company's operations, financial health, and future prospects. His recent purchase of ATAI shares is a strong vote of confidence in the company's direction and potential! After seeing a close friend struggle with mental health issues before self-treating successfully with psychedelics, Brand realized that patients across the world were underserved. Listen to Mr. Brand discuss the potential of psychedelics for the treatment of mental health here: [ The Market: Mental health conditions are increasing worldwide so ATAI is in a good market. “The Covid-19 pandemic exacerbated numerous social stressors that we know can increase the risk of both substance use and mental illness,” said [Dr. Nora Volkow]( director of the National Institute on Drug Abuse. “Perhaps one of the only benefits of the pandemic and the shift that our country has been going through is the increase in our willingness to acknowledge and talk about when we might be struggling or in need of support,” said Sarah Brummett, director of the [National Action Alliance for Suicide]( Prevention’s executive committee. Every year a staggering [13 million to 14 million Americans have major depression](. Of those who seek treatment, 30% to 40% will not get better or fully recover with standard antidepressants. Sadly, this puts them at greater risk of alcohol and drug abuse, hospitalization, and [suicide]( attempts. ATAI is now trying to flip the narrative on the failing mental health treatment space and is zooming in on the promising potential of psychedelics! The Company: ATAI currently has 8 clinical stage drug development programs with a focus on compound classes with prior evidence in humans; a portfolio approach to avoid binary risk and optimize the likelihood of success. You can read about them [HERE.]( The company’s Perception Neuroscience unit also teamed up with Japanese drugmaker Otsuka to develop R-ketamine in treating depression. This is the first major collaboration between a psychedelic-focused biotech and a big pharma company! ATAI is seeking multiple FDA approvals... Some of the company's development candidates represent significant opportunities to address unmet medical needs of patients living with mental health conditions... The company is working on several new treatments for mental health disorders including schizophrenia, anxiety, depression, opioid addiction, and PTSD. Promising News: ATAI reported that it completed the Phase 1 study of VLS-01 in healthy participants. “We are pleased to report the completion of the Phase 1 study of VLS-01, in which we demonstrated a supportive PK/PD profile of our proprietary OTF formulation of DMT,” said Florian Brand, CEO and Co-Founder of atai. “We plan to test a further optimized version of our OTF formulation in a forthcoming Phase 1b prior to initiating a Phase 2 study in TRD.” The Phase 1 study was designed to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of VLS-01 applied to the sublingual and buccal surfaces compared to intravenous (IV) DMT. The study enrolled a total of 74 healthy participants across three parts. The company has submitted a protocol to regulatory authorities and expects to enroll the first participant in a Phase 1b study in 1H 2024. It wasn't that long ago that ATAI released its second quarter financial report with updates on its programs. You can read clinical updates here: [finance.yahoo.com/news/atai-life-sciences-reports-second-105900191.html]( In Summary… Wall Street is known for many exciting areas that include healthcare, renewable energy, and blockchain. In recent years mental health has also become a loud topic in the market. The potential of the psychedelics industry has never been bigger. Long-stigmatized drugs like esketemine, MDMA and psilocybin are advancing rapidly through clinical trials for treatments of a range of mental health conditions. ATAI Life Sciences is embarking on the study of these drugs and others for their potential to treat mental health issues. Proponents of the treatments suggest positive impacts on mood, emotional processing, and overall brain health. According to ATAI’s website, the company’s mission is to “Pioneer the development of highly effective mental health treatments that address the unmet needs of patients.” ATAI expects to deliver several R&D milestones anticipated across key clinical programs through 2024. This is a company with a strong cash position that could be positioned to become a leader in mental health care treatments. Keep an eye out for any positive developments on the company’s studies. They could serve as a catalyst to create some major upward movement! ATAI is a little-known biotech company that could become a pioneer in mental health disorders and is one to keep high on the radar! Copyright 2023 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in ATAI. We have been currently compensated up to Twenty Five Thousand Dollars Cash ($25,000) via bank wire transfer from a third-party AmplifyIR, Inc for a 1 Day Marketing Program regarding ATAI with a start date of 10/18/2023. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Small Caps Daily 1334 Northampton St Easton, PA 18042 © 2023 | All rights reserved. [Unsubscribe](. [Twitter] [Facebook] [Instagram]